Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy

P Chelladurai, O Boucherat, K Stenmark… - British journal of …, 2021 - Wiley Online Library
Epigenetic mechanisms, including DNA methylation and histone post‐translational
modifications (PTMs), have been known to regulate chromatin structure and lineage‐specific …

Novel mechanisms targeted by drug trials in pulmonary arterial hypertension

DF Condon, S Agarwal, A Chakraborty, N Auer… - Chest, 2022 - Elsevier
Pulmonary arterial hypertension (PAH) is a rare disease associated with abnormally
elevated pulmonary pressures and right heart failure resulting in high morbidity and …

[HTML][HTML] 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension

SN Avdeev, OL Barbarash, AE Bautin… - Russian Journal of …, 2021 - russjcardiol.elpub.ru
2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic
pulmonary hypertension | Avdeev | Russian Journal of Cardiology Russian Journal of …

[HTML][HTML] Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2020

СН Авдеев, ОЛ Барбараш, АЕ Баутин… - Российский …, 2021 - cyberleninka.ru
Члены Рабочей группы подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Рабочей …

Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial

S Rosenkranz, J Feldman, VV McLaughlin… - The Lancet …, 2022 - thelancet.com
Background Data obtained in human lung tissue and preclinical models suggest that
oxidative stress and increased apoptosis signal-regulating kinase 1 (ASK1) activity might …

Interstitial lung disease in infancy and early childhood: a clinicopathological primer

FP Laenger, N Schwerk, J Dingemann… - European …, 2022 - Eur Respiratory Soc
Children's interstitial lung disease (chILD) encompasses a wide and heterogeneous
spectrum of diseases substantially different from that of adults. Established classification …

Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension

R Auth, JR Klinger - Expert Opinion on Investigational Drugs, 2023 - Taylor & Francis
Introduction Pulmonary arterial hypertension (PAH) is a progressive and life-threatening
disease. Approved treatment options currently primarily target abnormal cell signaling …

Novel molecular mechanisms involved in the medical treatment of pulmonary arterial hypertension

I Martin de Miguel, A Cruz-Utrilla, E Oliver… - International Journal of …, 2023 - mdpi.com
Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate
despite advances in diagnostic and therapeutic strategies. In recent years, significant …

[HTML][HTML] Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis

M Sinha, D Zabini, D Guntur, C Nagaraj… - Pharmacology & …, 2022 - Elsevier
Fine control over chloride homeostasis in the lung is required to maintain membrane
excitability, transepithelial transport as well as intra-and extracellular ion and water …

The effect of hypoxia-inducible factor inhibition on the phenotype of fibroblasts in Human and bovine pulmonary hypertension

CJ Hu, A Laux, A Gandjeva, L Wang, M Li… - American journal of …, 2023 - atsjournals.org
Hypoxia-inducible factor (HIF) has received much attention as a potential pulmonary
hypertension (PH) treatment target because inhibition of HIF reduces the severity of …